Improvement bioavailability of silymarin ameliorates severe dyslipidemia associated with metabolic syndrome

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F15%3A33155422" target="_blank" >RIV/61989592:15110/15:33155422 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023001:_____/15:00059567

Výsledek na webu

<a href="http://dx.doi.org/10.3109/00498254.2015.1010633" target="_blank" >http://dx.doi.org/10.3109/00498254.2015.1010633</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3109/00498254.2015.1010633" target="_blank" >10.3109/00498254.2015.1010633</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Improvement bioavailability of silymarin ameliorates severe dyslipidemia associated with metabolic syndrome

Popis výsledku v původním jazyce

1. To compare the effectiveness of different drug forms of silymarin: standardized extract of silymarin (SS), micronized silymarin (MS) and silymarin in the form of phytosome (PS) on dyslipidemia and liver fat accumulation in a model of metabolic syndrome, in non-obese hereditary hypertriglyceridemic rats. The second aim of this study was to slightly uncover the silymarin action on enzymes and proteins involved in cholesterol metabolism and excretion. 2. Silymarin administered to hereditary hypertriglyceridemic rats as dietary supplements (1%) for 4 weeks significantly lowered the plasma levels of triglycerides, total cholesterol and markedly increased HDL cholesterol level. Western blot analyses showed significant increase in the protein expression ofCYP7A1 and CYP4A and increase in protein expression of selected ABC transporters. Silymarin in the form of phytosome and micronized silymarin were more effective forms of silymarin. 3. These findings suggest that silymarin may favorably

Název v anglickém jazyce

Improvement bioavailability of silymarin ameliorates severe dyslipidemia associated with metabolic syndrome

Popis výsledku anglicky

1. To compare the effectiveness of different drug forms of silymarin: standardized extract of silymarin (SS), micronized silymarin (MS) and silymarin in the form of phytosome (PS) on dyslipidemia and liver fat accumulation in a model of metabolic syndrome, in non-obese hereditary hypertriglyceridemic rats. The second aim of this study was to slightly uncover the silymarin action on enzymes and proteins involved in cholesterol metabolism and excretion. 2. Silymarin administered to hereditary hypertriglyceridemic rats as dietary supplements (1%) for 4 weeks significantly lowered the plasma levels of triglycerides, total cholesterol and markedly increased HDL cholesterol level. Western blot analyses showed significant increase in the protein expression ofCYP7A1 and CYP4A and increase in protein expression of selected ABC transporters. Silymarin in the form of phytosome and micronized silymarin were more effective forms of silymarin. 3. These findings suggest that silymarin may favorably

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FR - Farmakologie a lékárnická chemie

OECD FORD obor

—

Projekt

<a href="/cs/project/GA13-10813S" target="_blank" >GA13-10813S: Přírodní polyfenolické látky v experimentální farmakologii metabolického syndromu</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Xenobiotica

ISSN

0049-8254

e-ISSN

—

Svazek periodika

45

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

751-756

Kód UT WoS článku

000361325400001

EID výsledku v databázi Scopus

—